SCHEMBL1940934

SCHEMBL1940934

Cc1cccc(NC(=O)Nc2cc(C(=O)c3cn(C(C)C)c4ncnc(N)c34)ccc2C)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.68
NTRK1 P04629 5/20 0.57
NTRK2 Q16620 5/20 0.57
NTRK3 Q16288 3/20 0.57
EGFR P00533 6/20 0.54
TEK Q02763 6/20 0.54
ERBB2 P04626 5/20 0.54
ERBB3 P21860 5/20 0.54
ERBB4 Q15303 5/20 0.54
AURKA O14965 2/20 0.49
IKBKE Q14164 1/20 0.49
AURKB Q96GD4 1/20 0.49
KCNH2 Q12809 3/20 0.48
KDR P35968 6/20 0.46
RET P07949 3/20 0.46
LCK P06239 2/20 0.46
SRC P12931 2/20 0.46
PDPK1 O15530 1/20 0.46
KIT P10721 4/20 0.46
FLT3 P36888 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1939633 0.93 PDGFRB (0.73) PDGFRBNTRK1NTRK2NTRK3EGFR
SCHEMBL1940426 0.92 PDGFRB (0.73) PDGFRBNTRK1NTRK2NTRK3EGFR
SCHEMBL1941042 0.91 PDGFRB (0.80) PDGFRBNTRK1NTRK2NTRK3EGFR
SCHEMBL1939252 0.90 EGFR (0.65) PDGFRBNTRK1NTRK2NTRK3EGFR
SCHEMBL1940922 0.89 PDGFRB (0.77) PDGFRBNTRK1NTRK2NTRK3EGFR
SCHEMBL1939949 0.89 PDGFRB (0.71) PDGFRBNTRK1NTRK2NTRK3EGFR
SCHEMBL1940991 0.89 PDGFRB (0.81) PDGFRBNTRK1NTRK2NTRK3EGFR
SCHEMBL4086172 0.88 NTRK1 (0.68) PDGFRBNTRK1NTRK2NTRK3EGFR
SCHEMBL1939484 0.88 PDGFRB (0.73) PDGFRBNTRK1NTRK2NTRK3EGFR
SCHEMBL1941515 0.88 PDGFRB (0.67) PDGFRBNTRK1NTRK2NTRK3EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578751-B1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PROD INC (US) 2011-06-15 EP claimed
US-7271262-B2 Pyrrolopyrimidine derivatives PFIZER INC (US) 2007-09-18 US claimed
EP-1578751-A1 PYRROLOPYRIMIDINE DERIVATIVES Pfizer Products Inc. (US) 2005-09-28 EP claimed
US-20050037999-A1 Pyrrolopyrimidine derivatives PFIZER INC 2005-02-17 US claimed
WO-2004056830-A1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2004-07-08 WO claimed
EP-1578751-B1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PROD INC (US) 2011-06-15 EP disclosed
US-7271262-B2 Pyrrolopyrimidine derivatives PFIZER INC (US) 2007-09-18 US disclosed
EP-1578751-A1 PYRROLOPYRIMIDINE DERIVATIVES Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20050037999-A1 Pyrrolopyrimidine derivatives PFIZER INC 2005-02-17 US disclosed
WO-2004056830-A1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050037999-A1 Pyrrolopyrimidine derivatives CCNA1, CCNT1, TP53 PDGFRB 2465/4885NTRK1 4135/4885NTRK2 4651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.